Patient characteristics
| Pt no. . | Age, y . | Time: CLL Dx to RS, mo . | Histology . | Pertinent genetic aberrations by FISH . | CK . | IGHV mutational status . | Clonally related . | No. of prior Tx . | Most recent prior line of Tx* . | Time on BTKi prior to leuka-pheresis, d . | Time from RT diagnosis to leuka-pheresis, d . | Concurrent BTKi . | Disease status at leuka-pheresis . | Max CRS grade . | Max ICANS grade . | Grade 3/4 events . | Best response (Lugano) . | Time to best response, d . | Follow-up, d . | Clinical status . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 50 | 24 | Non-GCB | Del(13q) | Yes | Unable to assess | Unable to assess | 3 | RDHAP/ RDHAX | N/A | 1111 | No | PR | 1 | 4 | No | CR | 72 | 345 | Ongoing CR |
| 2† | 46 | 38 | Non-GCB | Del(11q), MYC | Yes | Unmutated | Unable to assess | 6 | BTKi | 51 | 182 | Yes‡ | PD | 2 | 4 | No | CR | 92 | 296 | Received consolidation with MUD PBSCT, with ongoing CR |
| 3 | 64 | 197 | Non-GCB | del(13q), del(17p), MYC | Yes | Unmutated | Yes | 5 | BTKi | 24 | 50 | Yes | PR | 2 | 0 | No | CR | 93 | 210 | Ongoing CR, continues on BTKi |
| 4 | 76 | 89 | HGBCL | del(11q), del(13q), del(17p) | Yes | Unable to assess | Unable to assess | 3 | REPOCH | 3 | 119 | Yes | PD | 1 | 0 | Yes | PR | 107 | 210 | Relapsed disease at day 201 |
| 5 | 70 | 109 | Non-GCB | MYC | Yes | Unmutated | Yes | 3 | BTKi | 98 | 124 | Yes§ | PD | 4 | 3 | Yes | N/A | N/A | 49 | Died of infection |
| 6 | 72 | 36 | Non-GCB | del(11q) | Not done | Mutated | Yes | 2 | BTKi | N/A | 30 | Yes|| | SD | 2 | 1 | Yes | PR | 64 | 183 | Ongoing PR, continues on BTKi |
| 7 | 40 | 131 | Non-GCB | MYC | Not done | Mutated | Unable to assess | 5 | REPOCH | N/A | 120 | Yes¶ | SD | 2 | 0 | No | PR | 37 | 155 | Ongoing PR |
| 8 | 63 | 157 | GCB | None | Not done | Unmutated | Yes | 4 | BTKi | 120 | 143 | Yes | PD | 1 | 0 | No | CR | 81 | 86 | Ongoing CR, continues BTKi |
| 9 | 69 | 117 | HGBCL | Del (17p) | Yes | Unmutated | Yes | 5 | REPOCH | N/A | 215 | No | PR | 1 | 0 | No | CR | 92 | 93 | Ongoing CR |
| Pt no. . | Age, y . | Time: CLL Dx to RS, mo . | Histology . | Pertinent genetic aberrations by FISH . | CK . | IGHV mutational status . | Clonally related . | No. of prior Tx . | Most recent prior line of Tx* . | Time on BTKi prior to leuka-pheresis, d . | Time from RT diagnosis to leuka-pheresis, d . | Concurrent BTKi . | Disease status at leuka-pheresis . | Max CRS grade . | Max ICANS grade . | Grade 3/4 events . | Best response (Lugano) . | Time to best response, d . | Follow-up, d . | Clinical status . |
|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|---|
| 1 | 50 | 24 | Non-GCB | Del(13q) | Yes | Unable to assess | Unable to assess | 3 | RDHAP/ RDHAX | N/A | 1111 | No | PR | 1 | 4 | No | CR | 72 | 345 | Ongoing CR |
| 2† | 46 | 38 | Non-GCB | Del(11q), MYC | Yes | Unmutated | Unable to assess | 6 | BTKi | 51 | 182 | Yes‡ | PD | 2 | 4 | No | CR | 92 | 296 | Received consolidation with MUD PBSCT, with ongoing CR |
| 3 | 64 | 197 | Non-GCB | del(13q), del(17p), MYC | Yes | Unmutated | Yes | 5 | BTKi | 24 | 50 | Yes | PR | 2 | 0 | No | CR | 93 | 210 | Ongoing CR, continues on BTKi |
| 4 | 76 | 89 | HGBCL | del(11q), del(13q), del(17p) | Yes | Unable to assess | Unable to assess | 3 | REPOCH | 3 | 119 | Yes | PD | 1 | 0 | Yes | PR | 107 | 210 | Relapsed disease at day 201 |
| 5 | 70 | 109 | Non-GCB | MYC | Yes | Unmutated | Yes | 3 | BTKi | 98 | 124 | Yes§ | PD | 4 | 3 | Yes | N/A | N/A | 49 | Died of infection |
| 6 | 72 | 36 | Non-GCB | del(11q) | Not done | Mutated | Yes | 2 | BTKi | N/A | 30 | Yes|| | SD | 2 | 1 | Yes | PR | 64 | 183 | Ongoing PR, continues on BTKi |
| 7 | 40 | 131 | Non-GCB | MYC | Not done | Mutated | Unable to assess | 5 | REPOCH | N/A | 120 | Yes¶ | SD | 2 | 0 | No | PR | 37 | 155 | Ongoing PR |
| 8 | 63 | 157 | GCB | None | Not done | Unmutated | Yes | 4 | BTKi | 120 | 143 | Yes | PD | 1 | 0 | No | CR | 81 | 86 | Ongoing CR, continues BTKi |
| 9 | 69 | 117 | HGBCL | Del (17p) | Yes | Unmutated | Yes | 5 | REPOCH | N/A | 215 | No | PR | 1 | 0 | No | CR | 92 | 93 | Ongoing CR |
BTKi, Bruton tyrosine kinase inhibitor; CR, complete response; del/Del, deletion; Dx, diagnosis; FISH, fluorescent in situ hybridization; GCB, germinal center B; HGBCL, high-grade B-cell lymphoma; IGHV, immunoglobulin heavy chain variable region; Max, maximum; MUD PBSCT, matched unrelated donor peripheral blood stem cell transplant; MYC, MYC gene rearrangement; N/A, not applicable; PD, progressive disease; PR, partial response; Pt, patient; RDHAP, rituximab, dexamethasone, cytarabine, cisplatin; RDHAX, rituximab, dexamethasone, cytarabine, oxaliplatin; REPOCH, rituximab, etoposide, prednisone, vincristine, cyclophosphamide, doxorubicin; SD, stable disease; Tx, treatment.
Denotes prior line of therapy immediately preceding leukapheresis.
Patient received prior CAR-T therapy for CLL before developing RS.
Stopped BTKi when patient received MUD PBSCT.
Stopped BTKi 5 days after axi-cel due to toxicity.
Started on BTKi after leukapheresis and continued.
Started on BTKi after leukapheresis stopped prior to axi-cel infusion.